Sym004 in Patients With Advanced Solid Tumors

NIAID Data Ecosystem2026-03-06 收录

抗肿瘤药物I期临床试验

实体瘤治疗

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2088653 数据链接链接失效反馈

官方服务：

资源简介：

This trial is designed as a multi-centre, open label, dose-escalation, phase I trial and consists of five parts.

创建时间：

2010-03-15

Solid Tumor Therapeutics Market

实体瘤治疗

市场分析

The Solid Tumor Therapeutics report features an extensive regional analysis, identifying market penetration levels across major geographic areas. It highlights regional growth trends and opportunities

IMR REPORTS60

S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers

实体瘤治疗

药物疗效评估

The purpose of the study is to investigate the safety, tolerability, and preliminary anti-neoplastic activity of S095029 alone and in combination with Sym021 in patients with advanced solid tumor mali

NIAID Data Ecosystem50

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

实体瘤治疗

药物临床试验

This proposed Phase I clinical trial of SON-DP is an FIH, open-label, Phase Ia/Ib dose escalation and expansion study to evaluate the safety, tolerability, PK, and PD of SON-DP in participants with re

NIAID Data Ecosystem30

Patient characteristics (n = 104). *

肿瘤DNA检测

实体瘤治疗

*One patient was subsequently found to be ineligible for this study as he had not exhausted all lines of available antitumor treatments. **Includes non-small cell lung cancer (NSCLC), mesothelioma, sa

NIAID Data Ecosystem50

Table 3 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors

药代动力学

实体瘤治疗

Summary of PK parameters

NIAID Data Ecosystem40